She beat a rare liver cancer – and now works with her father to find more cures
Cancer scientist decides to study the tumour that once afflicted his small daughter – and now her work is adding to his project’s successElana Simon was 10 years old when she started to experience severe pains in her abdomen. For two years, puzzled doctors put forward diagnoses including lactose intolerance, Crohn ’s disease and stress. It was not until 2008 that they pinpointed the real cause. Elana was suffering from fibrolamellar carcinoma(FLC), a rare, usually lethal, form of liver cancer.“In a way, it was comforting to have a word for what was wrong with me after so much confusion about my condition,” Elana ...
Source: Guardian Unlimited Science - March 16, 2024 Category: Science Authors: Robin McKie Science Editor Tags: Cancer research Medical research Science UK news Source Type: news
New PD-1 Inhibitor Approved for Esophageal Cancer
(MedPage Today) -- The FDA approved tislelizumab (Tevimbra) for advanced/metastatic esophageal squamous cell carcinoma (ESCC) previously treated with chemotherapy, BeiGene announced.
The approval stipulates use of the PD-1 inhibitor in adults... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news
FAPI-PET/CT outperforms FDG-PET/CT in women with invasive breast cancer
This study underscores Ga-68 FAPI-PET/CT’s superiority over F-18 FDG-PET/CT for ILC,” the group concluded. A link to the full study can be found here. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: Will Morton Tags: Breast Source Type: news
FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
FDA Approves Tevimbra (tislelizumab-jsgr) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2024 Category: Drugs & Pharmacology Source Type: news
Imaging surveillance suggested for radial scars found on DBT
Imaging surveillance may be the way to go for monitoring radial scars without atypia found on screening digital breast tomosynthesis (DBT), research published March 13 in the American Journal of Roentgenology found.
In a study, Claire Crowley and Manisha Bahl, MD, from Massachusetts General Hospital in Boston, found that screening-detected radial scars without atypia at core-needle biopsy have a low upstaging rate to breast cancer of less than 2%.
“Our results, which show that surgical excision is not necessary for all patients with radial scars, could lead to a reduction in unnecessary surgery and could save patients ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Breast Imaging Source Type: news
Beta-defensin index: A functional biomarker for oral cancer detection
Cell Reports Mediine AccessPublished:March 04, 2024DOI:https://doi.org/10.1016/j.xcrm.2024.101447SummaryThere is an unmet clinical need for a non-invasive and cost-effective test for oral squamous cell carcinoma (OSCC) that informs clinicians when a biopsy is warranted. Human beta-defensin 3 (hBD-3), an epithelial cell-derived anti-microbial peptide, is pro-tumorigenic and overexpressed in early-stage OSCC compared to hBD-2. We validate this expression dichotomy in carcinoma in situ and OSCC lesions using immunofluorescence microscopy and flow cytometry. The proportion of hBD-3/hBD-2 levels in non-invasivel...
Source: Dental Technology Blog - March 12, 2024 Category: Dentistry Source Type: news
ARRS announces Resident/Fellow in Radiology awardees
The American Roentgen Ray Society (ARRS) is recognizing four radiologists, as well as their institutions and research projects, with its 2024 ARRS Resident/Fellow in Radiology Awards.
The following radiologists and their research projects are recognized as awardees:
ul.editorialList li {margin-bottom:6px;}
Melina Hosseiny, MD, University of California, San Diego. ARRS President’s Award for “Multi-task Ensemble Deep Learning for Differential Diagnosis of Pneumonia and Pulmonary Edema on Chest Radiograph.”
Ahmed Taher, MD, University of Texas Health Science Center at Houston. ARRS Executive Council Award for “...
Source: AuntMinnie.com Headlines - March 12, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: People in the News Source Type: news
Does breast radiation therapy raise risk of skin cancer?
Radiation therapy for breast cancer treatment leads to an increased risk of skin cancer, according to research published March 8 in JAMA Network Open.
A team led by Shawheen Rezaei from Stanford University found that the risk of non-keratinocyte skin cancer diagnosis such as melanoma and hemangiosarcoma after breast cancer treatment with radiation was more than 50% higher.
“Although occurrences of non-keratinocyte skin cancers are rare, physicians should be aware of this elevated risk to help inform follow-up care,” the Rezaei team wrote.
While breast cancer treatment strategies have improved over the decades, survi...
Source: AuntMinnie.com Headlines - March 11, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Breast Imaging Source Type: news
Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
FRIDAY, March 8, 2024 -- For patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin and pembrolizumab yield significantly better survival than chemotherapy, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2024 Category: Pharmaceuticals Source Type: news
Q & A: Immunotherapy in Renal Cell Carcinoma (RCC) Q & A: Immunotherapy in Renal Cell Carcinoma (RCC)
A collaboration and conversation between Medscape and Dr Karl D ' Silva on the impact of immunotherapy in renal cell carcinoma.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
First-Line Nivolumab Plus Chemo Approved for Bladder Cancer
(MedPage Today) -- The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, the agency announced... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
On March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news
Quality of life of patients treated with robotic surgery in the oral and maxillofacial region: a scoping review of empirical evidence
ConclusionCompared
to the conventional treatment modalities, TORS has demonstrated better
QoL, mostly in the domains related to oral functions such as swallowing
and speech, among patients treated with such. This improvement was most
evident within the initial post-operative year. (Source: Dental Technology Blog)
Source: Dental Technology Blog - March 7, 2024 Category: Dentistry Source Type: news